Consistency matters.
Continue to choose CARBAGLU.

CARBAGLU is the first FDA-approved medication indicated for adult and pediatric patients as:

  • Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylgutamate synthase (NAGS) deficiency.
  • Maintenance therapy for the treatment of chronic hyperammonemia due to N-acetylgutamate synthase (NAGS) deficiency.
  • Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA).
Learn more >

Acute Hyperammonemia due to Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)

Clinicians must act quickly to normalize acute high plasma ammonia levels.

Learn More >

Hyperammonemia due to
NAGS deficiency

Clinicians must act quickly to normalize high acute plasma ammonia levels. Maintenance therapy can treat chronic hyperammonemia due to NAGS deficiency.

Learn More >

Video Library


The library includes expert videos presenting undiagnosed urea cycle disorders as a cause of hyperammonemia (HA), the causes and detection of HA due to metabolic disorders, and videos showing how CARBAGLU works to treat HA due to PA, MMA, and NAGSD.

View Videos >

INDICATIONS AND USAGE

Carbaglu® (carglumic acid) tablets for oral suspension 200mg is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as:

  • Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency.
  • Maintenance therapy for the treatment of chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency.
  • Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA).

IMPORTANT SAFETY INFORMATION

  • Contraindications: None.
  • NAGS deficiency: Most common adverse reactions (≥13%) are: vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache.
  • PA and MMA: Most common adverse reactions (≥5%) are neutropenia, anemia, vomiting, electrolyte imbalance, decreased appetite, hypoglycemia, lethargy/stupor, encephalopathy and pancreatitis/lipase increased.
  • To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1‑800-FDA-1088 or www.fda.gov/medwatch.
  • If CARBAGLU is administered during pregnancy to women with NAGS deficiency, health care providers should report CARBAGLU exposure to the pregnancy pharmacovigilance program by calling 1-888-575-8344.
See LessSee More
X
X
X
X
X
X

You are about to leave the CARBAGLU.com website and enter a website operated by an independent third party. The links to third-party websites contained on CARBAGLU.com are provided solely for your convenience. Recordati Rare Diseases does not control the opinions, claims or comments contained on any third-party website linked to CARBAGLU.com, and your activities at those websites will be governed by the policies and practices of those third parties.

OK to proceed to third-party website CANCEL to return to CARBAGLU.com